BioLineRx (BLRX) Cash from Investing Activities (2013 - 2026)

BioLineRx's Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$337000.0 for Q4 2025.

• In Q4 2025, Cash from Investing Activities fell 103.02% year-over-year to -$337000.0; the TTM figure through Dec 2025 stood at -$8.5 million (down 129.09% YoY), while the FY2025 annual figure was -$8.5 million, down 129.09% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at -$337000.0, down from $3.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $16.7 million in Q1 2024, with the low at -$36.3 million in Q1 2021.
• The 5-year median for Cash from Investing Activities is $3.8 million (2022), against an average of -$597250.0.
• Peak annual rise in Cash from Investing Activities reached 267.16% in 2022, while the deepest fall reached 37437.5% in 2022.
• BioLineRx's Cash from Investing Activities stood at $4.0 million in 2021, then declined by 3.4% to $3.9 million in 2022, then tumbled by 628.09% to -$20.4 million in 2023, then surged by 154.7% to $11.2 million in 2024, then tumbled by 103.02% to -$337000.0 in 2025.
• Business Quant data shows BLRX's Cash from Investing Activities at -$337000.0 in Q4 2025, $3.7 million in Q3 2025, and -$3.7 million in Q2 2025.